December 23, 2004 -- Biotech moved higher today in a quiet pre-holiday session, far outpacing the gains of the broad market. The Centient Biotech 200™ gained 27 points to 3573, a .76% move and about twice the gain of the NYSE Composite or Nasdaq. We look at the FDA warning about COX-2 drugs, NitroMed’s completed NDA, Adolor’s plunging stock price, and Novartis’ promising new drug.
